Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercell, a developer of vaccines for the prevention and treatment of infectious diseases, has reported revenues of EUR13.09m for the fourth quarter ended 31 December 2010, a decrease of 59.3%, compared to EUR32.2m for the same period in 2009.
Subscribe to our email newsletter
Operating loss for the fourth quarter of 2010 was EUR198.94m, compared to EUR7.93m for the same period in 2009.
Intercell has generated gross profit was EUR7.63m, compared to EUR28.02m for the same period in last year.
For the full-year ended 31 December 2010, Intercell loss was EUR255.18m, compared to EUR18.35m.
Operating loss was EUR251.2m, compared to EUR30.46m.
Revenues for the full-year of 2010 were EUR34.21m, compared to EUR61.68m during the same period in the previous year.
Gross profit was EUR18.78m, compared to EUR49.23m in the same period of 2009.